Showing results (71-80 of 147) with videos related to

Sort By:
Pageof 15
International Clinical Psychopharmacology|November 24, 1999
Hypomania-like syndrome induced by olanzapineA E Simon, J M Aubry, L Malky, et al.
Bipolar Disorders|March 17, 2001
A theoretical reappraisal of mixed states: dysphoria as a third dimensionA Dayer, J M Aubry, L Roth, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|January 7, 2016
Can home-monitoring of sleep predict depressive episodes in bipolar patients?M Migliorini, S Mariani, G Bertschy, et al.
L'Encephale|July 1, 1985
[Dexamethasone test: suppressors and non-suppressors, what's the difference?]S Vandel, B Bonin, B Vandel, et al.
European Journal of Clinical Pharmacology|January 1, 1982
Biotransformation of amitriptyline in depressive patients: urinary excretion of seven metabolitesB Vandel, M Sandoz, S Vandel, et al.
Drug and Alcohol Dependence|December 5, 1998
Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term resultsA T Cucchia, M Monnat, J Spagnoli, et al.
European Journal of Clinical Pharmacology|January 1, 1982
Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical responseB Vandel, S Vandel, J M Jounet, et al.
L'Encephale|January 1, 1981
[Clomipramine and desmethylclomipramine: relationship between plasma levels and clinical effect (author's transl)]B Vandel, S Vandel, J M Jounet, et al.
Nordic Journal of Psychiatry|April 26, 2006
Olanzapine plasma level in relation to antimanic effect in the acute therapy of manic statesP Bech, M Gex-Fabry, J-M Aubry, et al.
L'Encephale|February 28, 2022
Impact of the first wave of the COVID-19 pandemic on French Health studentsF Rolland, A Frajerman, B Falissard, et al.
Pageof 15